11 results about "Radioimmunotherapy" patented technology

Provided are compositions and methods for treating Lewis Y antigen positive cancers in mammalian subjects by administering an effective amount of a radionuclide-labeled Lewis Y antigen targeting agent such as an antibody labeled with an alpha particle-emitting radionuclide such as 225Ac. The methods may further include administration of additional agents, such as radiosensitizing agents, immune checkpoint therapies, CD47 blockades, and / or DNA damage response inhibitors.

The invention belongs to the field of nano biological materials and tumor radioimmunotherapy, and particularly relates to a metal-polyamine nano compound as well as a preparation method and application thereof. The nano-composite is a core-shell structure nano-particle which is constructed by forming a hydrophobic core through coordination of divalent manganese ions and spermidine under the mediation of oleic acid and performing surface coating by adopting DSPE-PEG (Distearoyl Pyrrolidone-Polyethylene Glycol). Through coordination assembly of divalent manganese ions and spermidine and DSPE-PEG surface modification, a cGAS-STING pathway is synchronously activated to promote DCs maturation, the mitochondrial fatty acid oxidation function of CD8 + T cells is enhanced, and the radiotherapy-induced antitumor effect is enhanced.

This application relates to the field of biomedical technology, specifically disclosing a therapeutic probe targeting neuroblastoma GD2, adapted to the clinical needs of relapsed, refractory, and high-risk neuroblastoma. This therapeutic probe comprises paired diagnostic and therapeutic components, both using the humanized anti-GD2 monoclonal antibody hu3F8 as the sole targeting carrier; the diagnostic component is a zirconium-89-labeled deferoxamine-hu3F8 conjugate, and the therapeutic component is an actinium-225-labeled DOTA-hu3F8 conjugate. This application also discloses its preparation method, obtaining a high-purity product through three steps: antibody-chelating agent conjugation, radionuclide labeling, and purification. This probe system can be used to prepare a therapeutic drug composition for neuroblastoma, exhibiting strong targeting specificity, enabling imaging-guided precise radioimmunotherapy, and demonstrating good synergistic diagnostic and therapeutic effects.

The present invention provides a radionuclide-labeled PD-L1-targeting small protein, a preparation method therefor, and use thereof. Specifically, the present invention provides a radionuclide-labeled PD-L1-targeting small protein probe and a preparation method therefor. The probe is used for diagnosis of malignant tumors, accurate localization of lesions, efficacy monitoring, and radioimmunotherapy.

The invention discloses a multi-layer covered stent for unilateral controlled release of immune drugs and a preparation method and application thereof. The multi-layer covered stent comprises a substrate of a stent covered with an inner layer membrane, and the substrate is sequentially covered with a middle layer drug-loaded membrane and a blank pore membrane. The multi-layer covered stent is stable in structure and uniform in membrane layer distribution, the membrane layers and the stent are firmly combined, after the stent enters a tumor lesion site, medicine on the surface of the middle-layer medicine-carrying membrane is rapidly released to meet the treatment concentration, and after the outer-layer blank pore membrane absorbs lesion exudate, fiber network fusion occurs to generate small pores, so that the treatment effect is improved. The drug released by the middle-layer drug-loading membrane passes through pores of the outer-layer membrane at a relatively stable rate, and finally, a small amount of drug is slowly released at a stable rate along with degradation of the inner-layer membrane material, so that immune drugs and radiotherapy can form a continuous and stable synergistic treatment effect at a tumor part due to the zero-order release behavior; the tumor microenvironment immunity and the far-isolation effect are obviously improved, and the radiotherapy and immunity combined treatment of the malignant tumor accompanied by lumen obstruction is more efficiently realized.

This invention discloses a novel aggregation-induced luminescent substance targeted delivery method for a triple therapy combining chemotherapy, radiotherapy, and immunotherapy for tumors. This invention relates to the field of biotechnology, specifically to a novel aggregation-induced luminescent substance targeted delivery method for a triple therapy combining chemotherapy, radiotherapy, and immunotherapy for tumors. This invention provides a drug with inhibitory or anti-tumor activity against tumor cells. The active ingredient of the drug contains LNC@AIEgen, which is composed of inactivated cancer cells and Complex 1 loaded onto the inactivated cancer cells. The nanoplatform LNC@AIEgen designed in this invention is used for synergistic chemotherapy-radioimmunotherapy. This system fully utilizes the advantages of the delivery carrier, enhancing the anti-tumor therapeutic effect and acting as an anti-cancer vaccine. This simple yet effective strategy enables large-scale clinical treatment of cancer and contributes to personalized medicine.

The application belongs to the field of nanobiomaterials and tumor radioimmunotherapy, and particularly relates to a metal-polyamine nanocomposite as well as a preparation method and application thereof. The nanocomposite is a core-shell structure nanoparticle constructed by forming a hydrophobic core through coordination of divalent manganese ions and spermidine under mediation of oleic acid and coating the surface with DSPE-PEG. Through coordination assembly of divalent manganese ions and spermidine and surface modification with DSPE-PEG, the cGAS-STING pathway is simultaneously activated to promote maturation of DCs, and CD8 + T cell mitochondrial fatty acid oxidation function, and the anti-tumor effect induced by radiotherapy is enhanced.

The invention provides a multifunctional nano-composite, which is formed by electronegative DNA nano-flower and cationic liposome through electrostatic self-assembly, the DNA nano-flower takes single-stranded DNA containing CpG motif as a template, and is synthesized through Phi29 DNA polymerase rolling circle amplification reaction after T4 DNA ligase cyclization; the cationic liposome is composed of a single component cationic lipid NGPE, and an NR1D1 agonist SR9011 is entrapped in the cationic liposome. The invention also provides a preparation method of the nanocomposite. The invention also provides an application of the nano-composite in preparation of drugs for radioimmunotherapy of triple negative breast cancer. According to the invention, the technical problems of insufficient immune activation, high tumor radiation resistance, low hydrophilic / hydrophobic drug co-delivery efficiency, tumor microenvironment immunosuppression and the like in the existing radiotherapy are solved, and the radioimmunotherapy curative effect of the triple negative breast cancer is improved.

The application discloses a kind of bioactive polyamino acid nanocomposites, preparation method and purposes, by condensation reaction synthesis hyaluronic acid-block-poly amphiphilic block copolymer, by hydrophobic, electrostatic, metal coordination etc. Interaction covers CD73 small molecule inhibitor APCP and PD1 / PD-L1 inhibitor S7911, preparation HA@APCP / S7911.HA@APCP / S7911 is enriched in tumor area by EPR effect, under the joint action of hyaluronidase and low pH in tumor area, realize the release of APCP and S7911 in tumor tissue.APCP is inhibited CD73 enzyme activity, restores the metabolism and activity of NK cell, starts NK cell immune response;S7911 is inhibited after release in tumor tissue PD-L1 and PD-1 binding, blocks immune checkpoint and starts T cell immunity, combined with radiotherapy to improve antitumor immune response, amplify the range of effective immune response, for promoting the combined effect of radioimmunotherapy provides a new way of thinking.

A PD-L1-targeting nuclide protein probe and use thereof. Specifically, provided are a radionuclide-labeled PD-L1-targeting small protein probe and a preparation method therefor. The present invention is used for the diagnosis of malignant tumors, the precise localization of lesions, the monitoring of efficacy, and radioimmunotherapy.

This application relates to the fields of biomedicine and nuclear medicine, specifically disclosing a GD2-targeted therapy probe and its radioimmunotherapy application. It aims to address the limitations of existing probes in simultaneously achieving radionuclide labeling efficiency and antibody targeting activity, and their limited efficacy against relapsed / refractory neuroblastoma and minimal residual disease. This probe uses a hu3F8 antibody as the targeting carrier and Nota and DOTA as chelating agents to respectively match… 64 Cu、 177 Lu, a single antibody molecule coupled with 3-5 chelating agent molecules. This application also discloses a precise preparation method for the probe and its application in GD2-positive tumor PET imaging, radioimmunotherapy, SPECT monitoring, combined immunotherapy, and minimal residual disease clearance. This probe achieves integrated diagnosis and treatment, possessing high activity, high targeting, and low toxicity, showing excellent prospects for clinical translation.